Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs AstraZeneca plc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.38, while AstraZeneca plc trades at $158.47 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while YieldMax AMZN Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| AMZY | AZN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $209.48 |
52-Week Low | $9.98 | $147.06 |
Market Cap | — | $248.14B |
Enterprise Value | — | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.24, down 3.27% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions from YieldMax ETFs, though analyst reports express concerns about NAV erosion despite the high yield strategy.
The outlook for AMZY is mixed; the bullish technical trend and high dividend yield present income opportunities, but fundamental risks include potential NAV erosion and underperformance relative to Amazon. Investors should weigh the attractive weekly distributions against the sustainability of the option income strategy and amplified downside risks highlighted by analysts.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
